Profile

David D. Hurd, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

134 Ratings
12 Comments
 

David D. Hurd, M.D.

Professor,

Clinical Interests

Hodgkin's Disease, Blood and Marrow Transplant, Hematologic Malignancies, Lymphomas, Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas, Non-Hodgkin's Lymphoma, Clinical Trials, Hematopoietic Stem Cell Transplantation, Bone Marrow and Stem Cell Transplantation

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of Wisconsin-Madison, 1969
  • M.D., University of Illinois College of Medicine, 1974
  • Internship, Internal Medicine, University of Minnesota, 1975
  • Residency, Internal Medicine, University of Minnesota, 1977
  • Fellowship, University of Minnesota, 1979

Board Certifications

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

Memberships

  • Am Assn Of Cancer Research
  • AAAS
  • Am Coll Of Physicians
  • Am Soc of Clinical Oncology
  • Am Soc of Hematology

NPI Number

  • 1962481879
David D. Hurd, M.D.

Doctor Rating

4.7 out of 5

134 Ratings
12 Comments
 

David D. Hurd, M.D.

Professor, Hematology & Oncology

Research Interests

Hematopoietic Stem Cell Transplantation; Antineoplastic Combined Chemotherapy Protocols; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Stem Cell Transplantation
More »

Contact Information

Academic: 336-716-2088 | Department: 336-716-4464

Recent Publications

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin lymphoma. Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K.. Clin Lymphoma Myeloma Leuk. 2016;16(2):76-81.

Timing of salvage therapy and autologous hematopoietic cell transplant in relapsed hodgkin and non hodgkin lymphoma [abstract]. Lamar ZS, Fino N, Hurd D, Howard D, McIver ZA, Phillips GL, Vaidya R.. Biol Blood Marrow Transplant. 2016;22(3 Suppl 1):S127-S128.

Comparison of outcomes of two preparative regimens for lymphoma patients who are receiving autologous hematopoietic stem cell transplantations [abstract]. Kennedy L, Filipek R, Russell G, Hurd D.. Biol Blood Marrow Transplant. 2015;21(2 Suppl 1):S122.

Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ.. J Community Support Oncol. 2015;13(3):87-94.

Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM) [abstract]. Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Martin TG, Shea TC, Anderson KC, McCarthy PL.. J Clin Oncol. 2015;33(15 Suppl):8523.

Single institution retrospective study of infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, (EPOCH) plus /- rituximab (R) as first line therapy for aggressive non-Hodgkin lymphoma [abstract]. Lamar ZS, Fitzgerald N, Palmer JM, Gruber L, RaetskayaSolntseva O, Kennedy L, Vaidya R, Zamkoff KW, Hurd DD.. J Clin Oncol. 2015;33(15 Suppl):e19514.

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, McIver Z.. Clin Case Rep. 2015;3(7):615-617.

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. J Clin Oncol. 2015;33(15 Suppl):7015.

The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL.. Blood. 2015;126(23):2556.

Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (alliance) 50403 [abstract]. Kaplan LD, Jung SH, Stock W, Bartlett NL, Pitcher B, Byrd JC, Blum KA, LaCasce AS, Fulton N, Hsi ED, Hurd DD, Czuczman M, Leonard JP, Cheson BD.. Blood. 2015;126(23):337.

Large granular lymphocytic leukemia after allogeneic hematopoietic stem cell transplant [abstract]. Wang W, Bergman S, Hurd D, Zamkoff K, Beaty M.. Lab Invest. 2014;94(Suppl 1):384A.

Hematopoietic stem cell transplant candidate and designated proxy distress levels prior to hematopoietic stem cell transplantation. Duckworth KE, Forti AM, Russell GB, Naik S, Hurd DD, McQuellon RP.. Am J Hosp Palliat Care. 2014;31(8):853-856.

The process of advance care planning in HCT candidates and proxies: self-efficacy, locus of control, and anxiety levels. Duckworth KE, Forti AM, Russell GB, Naik S, Hurd D, McQuellon RP.. Am J Hosp Palliat Care. 2014;31(7):710-716.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ.. Br J Clin Pharmacol. 2014;78(5):1005-1013.

The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL.. Blood. 2014;124(21):3744.

Advance care planning information and distress in hematopoietic cell transplant candidates and proxies [abstract]. Duckworth K, Forti A, Russell G, Campbell C, Naik S, Hurd D, McQuellon R.. Psychooncology. 2013;22(Suppl 2):100-101.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA.. Invest New Drugs. 2013;31(5):1311-1320.

Outcomes of second transplants for disease recurrence or for myelodysplasia (MDS) developing after an initial transplant (Tx) [abstract]. Naik S, D'Agostino R Jr, Lamar Z, Graham RM, Vatca M, Agnew E, Higgins A, Levitan D, Hurd D.. Biol Blood Marrow Transplant. 2012;18(2 Suppl 2):S340-S341.

Fear of recurrence following hematopoetic stem cell transplantation [abstract]. McQuellon R, Duckworth K, Campbell C, Russell G, Naik S, Levitan D, Zamkoff K, McQuellon BT, Hurd D.. Psychooncology. 2012;21(Suppl 1):127.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Wendtner C-M, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, et al.. Leuk Lymphoma. 2012;53(3):417-423.

Lenalidomide after stem-cell transplantation for multiple myeloma. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A,.. N Engl J Med. 2012;366(19):1770-1781.

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED.. Haematologica. 2012;97(5):758-765.

A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG.. J Support Oncol. 2012;10(5):195-201.

A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, Fenske TS, Cashen A, Wagner-Johnston ND, Carson KR, Bartlett NL.. Blood. 2012;120(21):Abstr 1623.

Infectious complications associated with the use of antithymocyte globulin in reduced intensity allogeneic transplants [abstract]. Loth K, Naik S, Kennedy LA, Levitan D, Zamkoff K, Hurd D.. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S355-S356.

Transplant outcomes in multiple myeloma patients younger versus older than 60 years of age in the era of newer targeted agents [abstract]. Naik S, Shope D, Albright C, Graham R, Levitan D, Zamkoff K, D'Agostino R Jr, Hurd D.. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S252-S253.

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Hurd D, et al.. Leuk Res. 2011;35(3):329-333.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:. Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe L-A, Devine S, Farag S, Hurd D, Ball E, et al.. Biol Blood Marrow Transplant. 2011;17(4):558-565.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, Peterson BA, Nadler LM, Freedman A, Hurd DD, et al.. Leuk Lymphoma. 2011;52(4):587-596.

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW.. Ann Oncol. 2011;22(4):939-946.

A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory. Pomper GJ, Wilson E, Isom S, Hurd DD.. Transfusion. 2011;51(6):1291-1295.

Health related quality of life, depressive symptoms and distress before and after hematopoietic cell transplantation [abstract]. Campbell C, McQuellon R, Duckworth K, Russell G, Hurd D, Levitan D, Naik S, Zamkoff K, McQuellon B, Sommer J.. Psychooncology. 2011;20(Suppl 1):81.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, et al.. Blood. 2011;118(19):5119-5125.

Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S.. Blood. 2011;118(21):1546.

Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a phase I study [abstract]. Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, Hurd DD.. Blood. 2011;118(21):1705-1706.

Should the concern of myelodysplastic syndrome affect the decision of auto-SCT in lymphoma? [letter]. Keung YK, Levitan D, Zamkoff K, Hurd D.. Bone Marrow Transplant. 2010;45(2):407-408.

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Hurd DD, et al.. Int J Radiat Oncol Biol Phys. 2010;76(5):1305-1313.

Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Keung YK, Beaty MW, Pettenati M, Levitan D, Hurd DD.. Clin Lymphoma Myeloma Leuk. 2010;10(2):129-133.

Quality of survivorship, surveillance behavior and treatment satisfaction following hematopoietic cell transplantation [abstract]. McQuellon R, Campbell C, Russell G, Duckworth K, Sommer J, McQuellon B, Hurd D.. Psychooncology. 2010;19(Suppl 1):S98-S99.

The importance of timing of hematopoietic stem cell transplantation (HSCT) in patients with T-cell lymphomas (T-NHL) [abstract]. Ritter EM, Zamkoff KW, Levitan DA, Hurd DD.. Biol Blood Marrow Transplant. 2010;16(2 Suppl 2):S238.

Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104 [abstract]. McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA.. J Clin Oncol. 2010;28(15 Suppl Pt 1):577s.

Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma CALGB 100104 [abstract]. McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Levitan D, et al.. Blood. 2010;116(21):21-22.

Final results of the Phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study) [abstract]. Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Hurd DD, et al.. Blood. 2010;116(21):591-592.

Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma [abstract]. Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Hurd DD, et al.. Blood. 2010;116(21):815.

Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction. Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J.. J Soc Integr Oncol. 2010;8(4):140-147.

Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Beaty MW, Pettenati M, Hurd DH [sic] [Hurd DD], Keung Y.. Mod Pathol. 2009;22(Suppl 1):1161.

Assessing distress and depression in hematopoietic stem cell transplant patients [abstract]. McClure White G, Campbell C, Russell G, Duckworth K, Hurd D, McQuellon R.. Psychooncology. 2009;18(Suppl 1):S43.

A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Furman R, Hurd D, et al.. Haematologica. 2009;94(Suppl 2):371-372.

The transplant iron score as a predictor of stem cell transplant survival. Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Lovato J, Torti SV, Torti FM, Molnar I, et al.. J Hematol Oncol. 2009;2():article 44.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Hodgkin's Disease, Blood and Marrow Transplant, Hematologic Malignancies, Lymphomas, Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas, Non-Hodgkin's Lymphoma, Clinical Trials, Hematopoietic Stem Cell Transplantation, Bone Marrow and Stem Cell Transplantation
David D. Hurd, M.D.

David D. Hurd, M.D.

Professor, Hematology & Oncology

Doctor Rating

4.7 out of 5

David D. Hurd, M.D.134 Ratings
12 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.7
Wait time at clinic
4.0



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

5/26/2016

Excellent and compassionate.

12/23/2015

Happy with experience.

11/17/2015

I'm truly sorry that he is about to retire. He has been an excellent medical provider.

11/17/2015

*Dr. Hurd is an excellent doctor. He takes the time I need to answer my questions.

11/10/2015

Dr. Hurd is fabulous! I have only wonderful things to say about him. I hate that he is retiring for me but very happy for him. Not only is he an excellent Doctor, you also feel that he is a warm friend.

11/9/2015

As far as I'm concerned and from past experience WFU and their cancer team, including *Dr. Hurd and his PA's are the best. I'm always recommending Wake Forest.

10/28/2015

*Dr. Hurd and *Liz Holland, PA gets 10+++. Excellent providers.

9/29/2015

All good.

9/29/2015

Dr Hurd was always very friendly and carefully explained all facets of care and treatment.

9/16/2015

He is retiring and I wish him well!

8/25/2015

Dr. Hurd has ALWAYS been the most caring Dr. anyone could have. I will always remember him and have fond memories. He healed my wounds from a bad experience at Forsyth hospital.

8/25/2015

Questions submitting by emails always answered.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.